Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

PGR March 3, 2026

The Progressive Corporation Q4 2025 Earnings Call - $13B Comprehensive Income, 40% ROE and Regulator Approval to Raise Operating Leverage to 3.5x

Progressive closed 2025 with blockbuster results, adding roughly $9 billion in net premiums written, nearly 3.7 million policies, and generating almost $13 billion in comprehensive income, for a compr...

  • Progressive added almost $9 billion in net premiums written in 2025 and about 3.7 million policies in force.
  • Comprehensive income across operations and investments was nearly $13 billion in 2025, driving a comprehensive ROE of about 40%.
  • Management achieved a below-90 combined ratio in 2025, and the firm maintains a strategic mandate to grow at or below a 96 combined ratio.
  • +16 more takeaways
OFS March 3, 2026

OFS Capital Corporation Fourth Quarter 2025 Earnings Call - Balance-sheet breathing room, but NII and NAV under pressure

OFS reported Q4 2025 Net Investment Income of $0.20 per share, down from $0.22 the prior quarter, and Net Asset Value fell to $9.19 from $10.17. The quarter was marked by loan markdowns and portfolio ...

  • Net Investment Income was $0.20 per share in Q4 2025, down $0.02 sequentially from $0.22.
  • Net Asset Value per share dropped ~10% quarter-over-quarter to $9.19 from $10.17, driven primarily by markdowns of a few underperforming loans.
  • Management placed one loan on non-accrual (1.2% of portfolio at fair value) and moved one loan back to accrual (1.1% of portfolio) during the quarter; after quarter-end they exited a longstanding non-accrual for a partial recovery.
  • +12 more takeaways
SUPV March 3, 2026

Grupo Supervielle Q4 2025 Earnings Call - Loan Growth Outpaced Stress as Provisions Peaked and CET1 Rose to 15.4%

Q4 2025 was a transition quarter for Grupo Supervielle, marked by aggressive loan growth, a peak in provisioning and an improving margin backdrop. Loans rose 8% sequentially and 37% year over year, dr...

  • Total loans grew 8% sequentially and 37% year over year, with corporate lending rising 25% q/q and now representing 63% of the portfolio.
  • Retail balances declined 4% q/q and grew only 8% y/y, reflecting deliberate tightening of underwriting to prioritize risk adjusted returns.
  • NPL ratio increased to 5.0% from 3.9% in the prior quarter, consistent with system wide stress and prior rapid loan growth.
  • +12 more takeaways
LMB March 3, 2026

Limbach Holdings Q4 and FY 2025 Earnings Call - ODR-Led Revenue Surge, Pioneer Margin Wildcard

Limbach closed 2025 with a clear regime change, driven by owner direct repair and replacement work. Revenue jumped 24.7% to $646.8 million, adjusted EBITDA hit a record $81.8 million, free cash flow w...

  • Total 2025 revenue rose 24.7% to $646.8 million, the first substantial revenue growth since 2020 as the company executes its strategic shift to ODR.
  • ODR now dominates the business, representing about 75% of full year revenue and 77.6% of Q4 revenue, with total ODR revenue up 40.6% year over year.
  • Organic ODR growth was a robust 17% for the year; management is guiding 9% to 12% organic ODR growth for 2026.
  • +12 more takeaways
HLIO March 3, 2026

Helios Technologies Q4 FY2025 Earnings Call - Return to Growth, Record Cash, But Cautious Roadmap Amid Tariffs and Chip Risk

Helios closed fiscal 2025 with a clear turnaround: back-to-back quarters of profitable sales growth, stronger margins and record cash generation. Q4 revenue beat expectations and the company finished ...

  • Q4 revenue $211.0 million, up 17% year-over-year; on a pro forma basis excluding the CFP divestiture, Q4 sales rose 29% year-over-year.
  • Full year sales $839.0 million, up 4% reported; on a pro forma basis (ex-CFP) full year revenue rose about 6% — first year of top-line growth after multi-year declines.
  • Gross margin expanded to 33.6% in Q4, a 350 basis point improvement year-over-year, driven by higher volumes, mix and productivity gains.
  • +12 more takeaways
TDW March 3, 2026

Tidewater Inc. Q4 and Full Year 2025 Earnings Call - $500M Wilson’s Acquisition Signals Aggressive Capital Deployment Backed by Strong Free Cash Flow

Tidewater closed 2025 with a tidy but meaningful beat: revenue of $1.35 billion, EBITDA of about $598 million, and free cash flow of roughly $426 million, capped by a $151 million free cash flow quart...

  • Tidewater reported full year 2025 revenue of $1.35 billion and adjusted EBITDA of $598.1 million, with gross margin about 49.2% for the year.
  • Free cash flow was robust at $426 million for 2025, with Q4 free cash flow of $151.2 million driven largely by working capital improvements and Pemex cash collections.
  • Management completed a strategic vessel ownership realignment in Q4 that generated a one-time non-cash tax benefit of $201.5 million, which materially boosted reported net income for the year.
  • +12 more takeaways
FSTR March 3, 2026

L.B. Foster Q4 2025 Earnings Call - Strong Q4 finish lifts results, rail backlog recovery underpins 2026 optimism

L.B. Foster closed 2025 with a rescue-quarter performance, driven by a blistering fourth quarter that pushed full-year sales to $540 million and adjusted EBITDA to $39.1 million. Q4 sales jumped 25.1%...

  • Q4 2025 net sales were $160.4 million, up 25.1% year over year, the company’s strongest fourth quarter since 2018.
  • Adjusted EBITDA for Q4 was $13.7 million, up 89% versus prior year, driven by higher volumes and a 470 basis point improvement in SG&A as a percent of sales.
  • Full-year 2025 sales totaled $540 million, up 1.7% YoY, with adjusted EBITDA for the year of $39.1 million, up $5.5 million versus 2024.
  • +13 more takeaways
EVGO March 3, 2026

EVgo Q4 2025 Earnings Call - Achieved Adjusted EBITDA Breakeven; pivoting to aggressive 2026 scale-up

EVgo closed 2025 by hitting the milestone management set when the current CEO arrived: adjusted EBITDA breakeven in the fourth quarter and for the full year. Revenue jumped to $384 million, up 50% yea...

  • EVgo achieved adjusted EBITDA breakeven in Q4 2025 and for the full year, marking the company milestone set when the current CEO joined in late 2023.
  • Full year 2025 revenue was $384 million, a 50% increase versus 2024, with charging network revenue of $218 million (up 40%), extend revenue of $116 million (up 34%), and ancillary revenue of $49 million (up 239% driven in part by a $26 million contract buyout).
  • The network ended 2025 with 5,100 stalls in operation after adding ~1,200 stalls in 2025 and a record 500-stall deployment in Q4. EVgo now operates over 1,200 stations across 47 states.
  • +13 more takeaways
MASS March 3, 2026

908 Devices Fourth Quarter 2025 Earnings Call - Reached Q4 Positive Adjusted EBITDA as VipIR and XplorIR Drive FTIR-led Growth

908 Devices closed 2025 with clear signs the company’s turnaround is taking hold. Q4 revenue from continuing operations was $17.4 million, up 21% year over year, and management reported a positive adj...

  • Q4 2025 revenue from continuing operations was $17.4 million, up 21% year over year; full year revenue was $56.2 million, up 18% versus 2024.
  • 908 Devices achieved positive adjusted EBITDA in Q4 2025 of $0.7 million, a swing from a $4.0 million adjusted EBITDA loss in Q4 2024.
  • Full year adjusted EBITDA loss narrowed to $9.6 million, a 39% improvement versus 2024; management expects to cut the 2025 adjusted EBITDA loss roughly in half in 2026.
  • +12 more takeaways
SRRK March 3, 2026

Scholar Rock Q4 2025 Earnings Call - BLA resubmission and 2026 U.S. launch contingent on Catalent reinspection

Scholar Rock told investors it is ready to resubmit the apitegromab BLA and push for a U.S. launch in 2026, but the timing hinges squarely on a successful FDA reinspection of the Catalent Indiana fill...

  • Company is prepared to resubmit the apitegromab BLA and reaffirmed guidance of BLA re‑submission and U.S. launch following approval in 2026, contingent on a successful FDA reinspection of the Catalent Indiana facility.
  • FDA issued a warning letter to Catalent Indiana after the Type A meeting; Novo Nordisk submitted a remediation plan and FDA has had high-touch engagement, including sending a field team to the site.
  • Following the FDA field visit, routine manufacturing at Catalent resumed in late February and FDA stated it intends to conduct a site reinspection after those activities; Scholar Rock says a successful reinspection is the gating item for resubmission.
  • +12 more takeaways